All In Biotech

Drug Trial Radar · NCT00251459

A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Mar 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,000

Actual

Start

Nov 2005

Primary completion

Not stated

Study completion Sep 2007

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.

Conditions

  • Choroidal Neovascularization
  • Age-related Macular Degeneration

Interventions

  • rhuFab V2 (ranibizumab)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: The primary safety outcome measure is the incidence of SAEs (ocular and non ocular) evaluated through Month 12.
  2. Cohort 2: The primary safety outcome measure is the incidence of SAEs (ocular and non-ocular) and AEs (ocular and non-ocular) evaluated through Month 12.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.